Cas no 106463-17-6 ((R)-Tamsulosin Hydrochloride)
(R)-Tamsulosin Hydrochloride Chemical and Physical Properties
Names and Identifiers
-
- Tamsulosin hydrochloride
- (R)-(-)-5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzolsulfonamid hydrochloride
- 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-benzenesulfonamidehydrochloride
- TaMsulosin Hydrochloride, EP
- Tamsulosin Hydrochloride (200 mg)
- 5-[(R)-2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]]-2-methoxybenzenesulfonamide Hydrochloride
- (S)-5-(2-((2-(2-ethoxyphenoxy)ethyl)aMino)propyl)-2-MethoxybenzenesulfonaMide
- TAMSULOSIN HYDRCHLORIDE
- Harnal,YM 617, AMsulosin
- (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride
- (R)-Tamsulosin Hydro
- (R)-Tamsulosin Hydrochloride
- TAMSULOSIN HCL
- (R)-(-)-YM12617
- (R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride ee
- (R)-Tamsulosin
- (R)-TAMSULOSIN HYDROCHLORIDE,WHITE TO OFF-WHITE SOLID
- 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzene
- HARNAL
- LY253351
- Omic
- PRADIF
- TAMSOLUSIN HCL
- Tamsulosin (hydrochloride)
- TAMSULOSIN HYDROCHLORIDE , CERTIFIED REFERENCE MATERIAL
- Yutanal
- 5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide hydrochloride
- Omnic
- Flomax
- Amsulosin hydrochloride
- Urolosin
- Secotex
- Josir
- Alna
- Omix
- Expros
- YM 617
- YM617
- 11SV1951MR
- R-(-)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide hydrochloride
- (-)-(R)-5-(2-((2-(o-Ethoxyphenoxy)ethyl)
- Harnalidge OCAS
- -methoxybenzenesulfonamide hydrochloride
- BS-1019
- Y-617
- EU-617
- Tox21_112446_1
- Q-201777
- Tamsulosin Hydrochloride,(S)
- BT164440
- CHEMBL1200914
- LY-253351
- NS00076236
- (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2-methoxybenzenesulfonamide hydrochloride
- (R)-5-(2-((2-(2-ETHOXYPHENOXY)ETHYL)AMINO)PROPYL)-2-METHOXYBENZENESULFONAMIDE HCL
- D01024
- Amsulosin Hydrochloride;Tamsulosin hydrochloride
- Q27108379
- TAMSULOSIN HYDROCHLORIDE [JAN]
- T2749
- CAS-106463-17-6
- NCGC00167442-01
- SCHEMBL23428
- Flomax MR
- 5-[(2RS)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide Hydrochloride (Tamsulosin Racemate Hydrochloride)
- HY-B0661A
- DTXSID2046628
- TAMSULOSIN HYDROCHLORIDE [ORANGE BOOK]
- Tamsulosin hydrochloride, United States Pharmacopeia (USP) Reference Standard
- 106463-17-6
- AKOS015895342
- TAMSULOSIN HYDROCHLORIDE [WHO-DD]
- AKOS015995287
- C20H29ClN2O5S
- Tamsulosin hydrochloride, >=98% (HPLC)
- Benzenesulfonamide, 5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxy-, monohydrochloride, (R)-
- tamsulosine hydrochloride
- (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide monohydrochloride
- TAMSULOSIN HYDROCHLORIDE [USP-RS]
- SMR002543366
- Tamsulosinum hydrochloride
- YM-617
- BCP0726000042
- TAMSULOSIN HYDROCHLORIDE [USP IMPURITY]
- MFCD00922997
- (-)-LY 253352
- NCGC00167442-03
- Tamsulosin hydrochloride [USAN:USP:JAN]
- s4729
- DTXCID0026628
- TAMSULOSIN HYDROCHLORIDE [VANDF]
- TAMSULOSIN HYDROCHLORIDE [EP MONOGRAPH]
- Tamsulosin hydrochloride, European Pharmacopoeia (EP) Reference Standard
- Racemic tamsulosin hydrochloride
- 5-[(R)-2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]]-2-methoxybenzenesulfonamideHydrochloride
- DA-78184
- (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)-2
- 5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide;hydrochloride
- TAMSULOSIN HYDROCHLORIDE [MART.]
- TAMSULOSIN HYDROCHLORIDE [USAN]
- TAMSULOSIN HYDROCHLORIDE [USP MONOGRAPH]
- CHEBI:9399
- R-(-)-YM-12617
- 128332-25-2
- YM-12617-1
- Tamsulosin hydrochloride, British Pharmacopoeia (BP) Reference Standard
- Flomax (TN)
- (-)-(R)-5-(2-((2-(o-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide monohydrochloride
- Tox21_112446
- Tamsulosin hydrochloride (JP17/USP)
- CCG-269178
- 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide hydrochloride
- UNII-11SV1951MR
- Harnal (TN)
- MLS003899197
- Tamsulosin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
- AlnaOCAS
- Tamsulosina hydrochloride
- tamsulosin.HCl
- JALYN COMPONENT TAMSULOSIN HYDROCHLORIDE
- (-)-(R)-5-(2-((2-(o-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzene sulfonamide monohydrochloride
- (R)-Tamsulosin hydrochloride- Bio-X
-
- MDL： MFCD00922997
- Inchi： InChI=1S/C20H28N2O5S.ClH/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24;/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24);1H/t15-;/m1./s1
- InChI Key： ZZIZZTHXZRDOFM-XFULWGLBSA-N
- SMILES： Cl[H].S(C1=C(C([H])=C([H])C(=C1[H])C([H])([H])[C@@]([H])(C([H])([H])[H])N([H])C([H])([H])C([H])([H])OC1=C([H])C([H])=C([H])C([H])=C1OC([H])([H])C([H])([H])[H])OC([H])([H])[H])(N([H])[H])(=O)=O
Computed Properties
- Exact Mass: 408.17200
- Monoisotopic Mass: 444.149
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 29
- Rotatable Bond Count: 11
- Complexity: 539
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 108
Experimental Properties
- Color/Form: No data available
- Melting Point: 230°C(dec.)(lit.)
- Boiling Point: No data available
- Flash Point: No data available
- Solubility: DMSO: >10mg/mL
- PSA: 108.26000
- LogP: 4.51290
- Merck: 9049
- Specific Rotation: -17.5° - -20.5° (c=1, H2O)
- Vapor Pressure: No data available
(R)-Tamsulosin Hydrochloride Security Information
-
Symbol:
- Prompt：warning
- Signal Word：Warning
- Hazard Statement： H302,H315,H319,H335
- Warning Statement： P261,P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： 22-36/37/38
- Safety Instruction： 26
- RTECS：DB2430000
-
Hazardous Material Identification：
- Storage Condition：?20°C
(R)-Tamsulosin Hydrochloride Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R002702-100mg |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | 98% | 100mg |
￥347 | 2023-09-11 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R002702-500mg |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | 98% | 500mg |
￥1321 | 2023-09-11 | |
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | PHR1524-200MG |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | 200mg |
￥3367.57 | 2025-01-16 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | BP876 |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | 100mg |
￥2168.09 | 2023-04-24 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | Y0000650 |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | European Pharmacopoeia (EP) Reference Standard | ￥2654.27 | 2022-02-23 | ||
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 1643260-200MG |
(R)-Tamsulosin Hydrochloride |
106463-17-6 | 200mg |
￥30702.96 | 2023-09-06 | ||
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | T96900-100mg |
Tamsulosin hydrochloride |
106463-17-6 | 99% | 100mg |
￥270.0 | 2023-09-06 | |
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | T96900-250mg |
Tamsulosin hydrochloride |
106463-17-6 | 99% | 250mg |
￥480.0 | 2023-09-06 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T0210-25 mg |
Tamsulosin hydrochloride |
106463-17-6 | 99.76% | 25mg |
￥340.00 | 2022-04-26 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T0210-50 mg |
Tamsulosin hydrochloride |
106463-17-6 | 99.76% | 50mg |
￥475.00 | 2022-04-26 |
(R)-Tamsulosin Hydrochloride Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
(R)-Tamsulosin Hydrochloride Related Literature
-
Shengli Han,Peng Zhang,Fen Wei,Sicen Wang Anal. Methods 2012 4 3351
-
Fen Wei,Xiaxi Zhang,Ping Cui,Xilan Gou,Sicen Wang J. Mater. Chem. B 2021 9 683
-
Qingqing Wang,Zihou Liu,Rui Wang,Run Li,Xiaoru Lian,Yanquan Yang,Jiao Yan,Zhiqi Yin,Guangji Wang,Jianguo Sun,Ying Peng Food Funct. 2023 14 3051
-
Yunlu Liu,Qian Xiang,Qi Liang,Jianyou Shi,Jun He Food Funct. 2022 13 7448
Additional information on (R)-Tamsulosin Hydrochloride
Professional Introduction to (R)-Tamsulosin Hydrochloride (CAS No. 106463-17-6)
(R)-Tamsulosin Hydrochloride, identified by the chemical compound code CAS No. 106463-17-6, is a highly specialized pharmaceutical compound that has garnered significant attention in the field of medicinal chemistry and urology. This compound is the hydrochloride salt of (R)-tamsulosin, a selective α1-adrenergic receptor antagonist, which is widely recognized for its therapeutic applications in the management of benign prostatic hyperplasia (BPH). The unique stereochemistry of (R)-tamsulosin Hydrochloride contributes to its distinct pharmacological profile, making it a subject of extensive research and development.
The pharmacological activity of (R)-Tamsulosin Hydrochloride is primarily attributed to its ability to selectively block α1-adrenergic receptors in the prostate, bladder neck, and urethra. This selective blockade leads to relaxation of the smooth muscles in these areas, thereby improving urinary flow and alleviating the symptoms associated with BPH. Unlike its enantiomer, (S)-tamsulosin, which exhibits a broader range of α1-adrenergic receptor selectivity, (R)-Tamsulosin Hydrochloride has been found to have a more focused action on the α1A-adrenergic receptor subtype, which is predominantly expressed in the prostate gland. This specificity not only enhances its therapeutic efficacy but also minimizes potential side effects associated with non-selective α1-blockers.
Recent advancements in medicinal chemistry have highlighted the importance of enantiopure compounds in achieving optimal therapeutic outcomes. (R)-Tamsulosin Hydrochloride represents a prime example of an enantiopure drug that has been meticulously designed to target specific biological pathways with high precision. The development of this compound has been driven by the need for more effective and safer treatments for BPH, a condition that significantly impacts the quality of life for millions of men worldwide.
In clinical settings, (R)-Tamsulosin Hydrochloride has demonstrated remarkable efficacy in reducing symptoms such as urinary frequency, nocturia, and hesitancy. Its ability to provide rapid relief while maintaining a favorable side effect profile has made it a preferred choice for healthcare professionals managing BPH. Moreover, studies have shown that (R)-Tamsulosin Hydrochloride can be administered at lower doses compared to non-selective α1-blockers, thereby reducing the risk of systemic side effects such as dizziness and hypotension.
The structural integrity and stereochemical purity of (R)-Tamsulosin Hydrochloride are critical factors that contribute to its pharmacological efficacy. The hydrochloride salt form enhances solubility and bioavailability, ensuring that the compound is effectively absorbed and utilized by the body. This formulation has been optimized through rigorous pharmacokinetic studies to ensure consistent therapeutic levels over an extended period.
Recent research has also explored the potential applications of (R)-Tamsulosin Hydrochloride beyond its traditional use in BPH treatment. Studies have suggested that this compound may have additional benefits in managing other urological conditions, such as detrusor overactivity and neurogenic bladder dysfunction. The ability of (R)-Tamsulosin Hydrochloride to modulate smooth muscle tone in the urinary tract makes it a promising candidate for further investigation in these areas.
The synthesis and production of (R)-Tamsulosin Hydrochloride have been refined through advanced chemical methodologies to ensure high yield and purity. The use of chiral resolution techniques allows for the isolation of the active enantiomer with minimal impurities, thereby enhancing both safety and efficacy. These advancements in synthetic chemistry have not only improved the accessibility of (R)-Tamsulosin Hydrochloride but also set new standards for enantiopure drug development.
The regulatory landscape for pharmaceutical compounds like (R)-Tamsulosin Hydrochloride is stringent, requiring extensive preclinical and clinical trials to establish safety and efficacy profiles before market approval. These trials have consistently demonstrated the positive impact of (R)-Tamsulosin Hydrochloride on patients with BPH, reinforcing its status as a cornerstone therapy in urological medicine. The ongoing research into novel applications and formulations continues to expand its therapeutic potential.
In conclusion, (R)-Tamsulosin Hydrochloride (CAS No. 106463-17-6) stands as a testament to the progress made in targeted pharmaceutical therapy. Its selective action on α1-adrenergic receptors, combined with its favorable pharmacokinetic properties, makes it an invaluable asset in managing BPH and potentially other urological disorders. As research continues to uncover new insights into its mechanisms of action and therapeutic applications, (R)-Tamsulosin Hydrochloride is poised to remain at the forefront of urological treatment options.
106463-17-6 ((R)-Tamsulosin Hydrochloride) Related Products
- 91-53-2(Ethoxyquin)
- 106133-20-4(Tamsulosin)
- 95266-40-3(Trinexapac-ethyl)
- 106138-88-9(Benzenesulfonamide,5-[(2S)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-)
- 70-55-3(4-methylbenzene-1-sulfonamide)
- 112244-38-9(5-(2-Aminopropyl)-2-methoxybenzenesulphonamide)
- 28395-03-1(Bumetanide)
- 119413-54-6(Topotecan Hydrochloride)
- 1836-62-0(2-(2-Aminoethoxy)anisole)
- 456-55-3((Trifluoromethoxy)benzene)
